NAD+ 1000mg Review

NAD+ is one of the most studied small-molecule cofactors in modern biochemistry. Interest has accelerated sharply since the early 2010s, when Guarente, Sinclair, and colleagues established a mechanistic link between declining cellular NAD+ pools and the aging phenotype in both rodent models and human tissue. ^[1] The compound functions simultaneously as a hydride-transfer coenzyme in hundreds of redox reactions and as a consumed substrate for signaling enzymes including sirtuins, PARP poly-ADP-ribose polymerases, and cyclic-ADP-ribose synthases. ^[2] That dual role gives it an unusually broad footprint in cell biology, which is why 1,000 mg vials intended for bulk cell-culture or animal-study applications have become a staple purchase for longevity-biology labs.

This review consolidates the structural chemistry, published mechanism data, pharmacokinetic parameters, and purity standards a researcher should understand before integrating NAD+ into a laboratory workflow. Where evidence is strong, we say so plainly; where it is contested or derived primarily from rodent data, we flag that too.

Editor's Verdict

NAD+ at 1,000 mg bulk format occupies a well-defined niche: it is the reference-grade substrate for any laboratory investigating sirtuin biology, PARP-dependent DNA repair, mitochondrial biogenesis, or the metabolic consequences of NAD+ depletion. The scientific rationale is not speculative. NAD+ levels decline measurably with age in multiple mammalian tissues, ^[3] PARP hyperactivation after genotoxic stress can deplete cellular NAD+ by 80% within minutes, ^[4] and genetic or pharmacological restoration of NAD+ pools extends healthspan metrics in multiple rodent models. ^[5]

What distinguishes a 1,000 mg vial from smaller formats is purely practical: at typical cell-culture working concentrations of 0.5-10 mM, a single 96-well-plate experiment consumes relatively little material, but longitudinal animal studies consuming intraperitoneal doses of 300-500 mg/kg in mouse models benefit from a bulk supply that keeps inter-experiment variability low. ^[6]

The main limitations are stability-related rather than scientific. NAD+ degrades to NADH, NAAD, and nicotinamide under light, elevated temperature, or aqueous alkaline conditions, so verified cold-chain handling and freshly prepared working solutions are non-negotiable for reproducible data. The Apollo Peptide Sciences 1,000 mg format is supplied lyophilized and requires cold storage; researchers should request a current certificate of analysis (CoA) showing HPLC purity 95% or greater and confirm identity via mass spectrometry.

Specifications

Researchers sourcing NAD+ for the first time should note the molecular weight carefully. Some suppliers list the sodium salt form (MW approximately 709.4 g/mol) rather than the free acid. When preparing molar solutions, the form used on the CoA must match the MW entered into the calculation, or target concentrations will be systematically off by roughly 7%.

What It Is, Chemistry, Origin, and Structural Detail

Chemical Identity

β-Nicotinamide adenine dinucleotide in its oxidized form (NAD+) is a dinucleotide comprising two nucleotides joined by a 5'-5' pyrophosphate bridge. The adenosine half consists of adenine attached to ribose through an N-glycosidic bond; the nicotinamide half consists of nicotinamide (the amide of nicotinic acid, vitamin B3) attached to a second ribose also in N-glycosidic linkage. The critical functional group is the quaternary nitrogen of the nicotinamide ring, which carries a formal positive charge and accepts a hydride ion (H-) during reduction to NADH. ^[1]

The molecular formula C21H27N7O14P2 gives a free-acid molecular weight of 663.43 g/mol. PubChem CID 5893 records the InChI key BAWFJGJZGIEFAR-NNYOXOHSSA-N and provides reference spectral data useful for identity verification. The UV spectrum shows characteristic absorbance peaks at approximately 260 nm (adenine ring, present in both NAD+ and NADH) and at 340 nm only in NADH, a feature exploited in enzymatic assays using the NAD+/NADH ratio as a readout. ^[1]

Biosynthesis and Endogenous Pools

Cells synthesize NAD+ through three convergent pathways. The de novo pathway converts dietary tryptophan to quinolinic acid and then to nicotinic acid mononucleotide (NaMN) via a series of enzymatic steps regulated by ACMSD (alpha-amino-beta-carboxymuconate-semialdehyde decarboxylase). ^[2] The Preiss-Handler salvage pathway captures nicotinic acid (NA) and converts it through NaMN and NAAD to NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase). The most metabolically active route in most mammalian cell types is the nicotinamide salvage pathway: nicotinamide released by NAD-consuming enzymes is converted by NAMPT (nicotinamide phosphoribosyltransferase) to NMN, which NMNAT then adenylates to NAD+. ^[2]

NAMPT is rate-limiting in the salvage pathway and declines with age in multiple tissues, which is one mechanistic explanation for the observed decline in tissue NAD+ levels across species. ^[3] In young adult rodents, whole-blood NAD+ concentrations run approximately 300-600 nmol per mL; by 24 months, tissue NAD+ in liver and skeletal muscle drops by 50% or more relative to 3-month-old controls. ^[5]

Structural Distinction from Related Metabolites

Researchers working with NAD+ must distinguish it from several closely related molecules that have distinct biological roles and different supplier-catalog identities:

• NADH (reduced NAD+): accepts and donates electrons in the electron transport chain; MW 665.44 g/mol; UV absorption shifts to 340 nm.
• NADP+: carries an additional 2'-phosphate on the adenosine ribose; MW 743.41 g/mol; serves as reductant in anabolic reactions and antioxidant defense.
• NMN (nicotinamide mononucleotide): the immediate biosynthetic precursor to NAD+; MW 334.22 g/mol; increasingly studied as a cell-permeable NAD+ precursor. ^[7]
• NR (nicotinamide riboside): one step upstream of NMN; MW 255.23 g/mol.

For experiments designed to test NAD+ signaling specifically, researchers should use NAD+ directly rather than precursors, because precursor-to-NAD+ conversion efficiency varies by cell type and can confound interpretation of dose-response relationships.

Mechanism of Action

NAD+ participates in biology through two operationally distinct modes: as a co-substrate cycling between oxidized (NAD+) and reduced (NADH) states in hydride-transfer reactions, and as a consumed substrate for signaling enzymes that cleave the N-glycosidic bond. The second mode is relevant to most longevity-biology research applications and is treated in detail here.

Sirtuin Activation and Epigenetic Regulation

Sirtuins (SIRT1-7 in mammals) are NAD+-dependent lysine deacylases. They catalyze the transfer of acyl groups from substrate lysine residues to the ADP-ribose moiety of NAD+, releasing nicotinamide and the O-acyl-ADP-ribose product. ^[2] Because nicotinamide is a product-feedback inhibitor of sirtuins, the cellular NAD+/NADH ratio and total NAD+ concentration together regulate sirtuin activity in a concentration-dependent manner. Km values for NAD+ in SIRT1 and SIRT3 range from approximately 94-880 µM depending on peptide substrate and assay conditions, positioning them to respond proportionally to physiological NAD+ fluctuations. ^[8]

SIRT1 deacetylates p53, NF-kB, FOXO transcription factors, and PGC-1alpha. Through PGC-1alpha deacetylation and co-activation of NRF2, SIRT1 drives transcription of mitochondrial biogenesis genes (TFAM, NRF1) and antioxidant enzymes. ^[9] SIRT3, localized to the mitochondrial matrix, deacetylates and activates SOD2 (manganese superoxide dismutase) and LCAD (long-chain acyl-CoA dehydrogenase), linking NAD+ availability directly to mitochondrial ROS homeostasis and fatty acid oxidation. ^[10]

SIRT6 deacetylates histone H3K9 and H3K56 at telomeres and at the promoters of glycolytic genes, functioning as a metabolic gatekeeper that suppresses the Warburg shift seen in senescent cells. ^[11] Loss of SIRT6 in mice produces a progeroid syndrome with severe metabolic defects, and SIRT6-overexpressing male mice live approximately 14.5% longer than controls, a finding that has motivated considerable interest in NAD+ as a sirtuin activator. ^[11]

PARP-Dependent DNA Repair

The poly-ADP-ribose polymerase (PARP) family, particularly PARP1, consumes NAD+ at high rates during the response to DNA strand breaks. A single PARP1 molecule can attach up to 200 ADP-ribose units per activation event, using one NAD+ molecule per addition. Under severe genotoxic stress, PARP1 hyperactivation can deplete cellular NAD+ by 80-95% within 15-30 minutes, triggering a bioenergetic collapse that contributes to parthanatos cell death. ^[4]

The productive side of PARP activity is the scaffolding of DNA repair proteins at break sites. PARP1-generated poly-ADP-ribose chains recruit XRCC1, DNA ligase III, and the base-excision repair machinery, accelerating single-strand break resolution. ^[12] Research designs aiming to study NAD+ effects on DNA repair typically use doses sufficient to replenish PARP-depleted pools while using PARP inhibitors (olaparib, niraparib) as negative controls to isolate the PARP-dependent fraction of NAD+ consumption.

CD38 and Cyclic-ADP-Ribose Signaling

CD38 is a multifunctional ecto-enzyme and the dominant NAD+-consuming enzyme in several tissues including heart, liver, and immune cells. It catalyzes both the conversion of NAD+ to cyclic-ADP-ribose (cADPR) and the hydrolysis of cADPR and NAADP, making it a central node in calcium-mobilization signaling. ^[13] CD38 expression increases substantially with age and in inflammatory microenvironments, and CD38 knockout mice maintain higher tissue NAD+ levels at 12 months than wild-type littermates. ^[13]

The mechanistic implication for research design is that experiments intended to study sirtuin-mediated effects of NAD+ supplementation may be confounded by CD38 activity consuming a large fraction of exogenously added NAD+. Co-treatment with the CD38 inhibitor 78c or apigenin is therefore common in studies designed to isolate sirtuin-specific signaling from total NAD+ supplementation effects. ^[14]

Mitochondrial Biogenesis and Energy Metabolism

Beyond sirtuin signaling, elevated NAD+ directly supports the electron transport chain by providing the NADH substrate for Complexes I, and shifts the NAD+/NADH ratio toward a more oxidized state that thermodynamically favors fatty acid beta-oxidation. ^[9] In C2C12 myotubes, pharmacological restoration of NAD+ to levels equivalent to young adult rodent muscle produced a 30-40% increase in maximal mitochondrial oxygen consumption rate (OCR), measured by Seahorse XF assay. ^[15]

NMNAT3, the mitochondrial isoform of NMN adenylyltransferase, synthesizes intramitochondrial NAD+ from NMN and ATP in a compartment that is inaccessible to cytoplasmic NAD+, a finding that complicates simple supplementation models. ^[16] Mitochondrial NAD+ pools appear to be regulated semi-independently from cytoplasmic pools, and the relative contribution of precursor supplementation to each compartment is an active research question. ^[16]

Tissue Distribution of NAD+ Biology

NAD+ biology is not uniform across tissues. Liver has among the highest steady-state NAD+ concentrations (estimated 200-600 nmol/g wet weight) and is the primary site of de novo synthesis; it also expresses high NAMPT and SIRT3 activity. ^[3] Skeletal muscle accounts for roughly 40% of whole-body NAD+ consumption given its mass, with SIRT1 and SIRT3 regulating mitochondrial density in response to exercise and fasting. ^[5] Brain NAD+ pools are tightly regulated and relatively lower in concentration than liver; they are particularly vulnerable to PARP hyperactivation following ischemia-reperfusion injury. ^[4] Adipose tissue NAD+ influences insulin signaling through SIRT1-mediated deacetylation of AKT-interacting proteins, contributing to systemic glucose homeostasis. ^[17]

What the Research Says

Study 1, Yoshino et al., 2011: NAD+ Deficiency in Diet-Induced Obesity

Yoshino and colleagues published a landmark rodent study in Cell Metabolism establishing that diet-induced obesity and aging both produce a state of intracellular NAD+ deficiency, identifiable by reduced NAMPT expression in white adipose tissue. ^[5] The experimental design used 12-month-old C57BL/6 mice alongside high-fat-diet (HFD) mice at 5 months; both groups showed markedly reduced WAT NAD+ levels compared to young lean controls.

The intervention arm administered NMN (500 mg/kg/day, intraperitoneal, 7 days) to normalize WAT NAD+ levels. However, the mechanistic significance for direct NAD+ research lies in the dose-response profiling: the authors showed a direct correlation between tissue NAD+ concentration and SIRT1 activity (measured as p53-K379 acetylation status), with NAD+ concentrations below approximately 100 nmol/g wet weight associated with nearly complete SIRT1 inactivation. This threshold effect has important implications for cell-culture experiment design, where concentrations below the Km of SIRT1 (approximately 100-200 µM in intact cells) cannot be expected to activate sirtuin pathways.

A limitation of this study is that NMN was used rather than direct NAD+ supplementation, meaning the NAD+ elevation observed reflects endogenous biosynthetic capacity and not direct NAD+ uptake. Subsequent cell-free assays in the same paper confirmed that adding NAD+ at 100-500 µM to cell lysates dose-dependently increased SIRT1 deacetylase activity, providing a direct substrate-concentration-activity relationship. The study's contribution to the bulk NAD+ research context is its establishment of tissue NAD+ thresholds as functional endpoints for dose calibration in animal work. ^[5]

Study 2, Massudi et al., 2012: Age-Associated Decline in Human Tissue NAD+

Massudi and colleagues conducted one of the first studies directly measuring NAD+ decline in human tissue, analyzing post-mortem liver, skin, and skeletal muscle samples from donors aged 22-91 years. ^[3] Using a validated fluorometric cycling assay, the authors reported a significant negative correlation (r = -0.77, p < 0.001) between donor age and NAD+ concentration in human liver, with a decline from approximately 600 nmol/g wet weight in the youngest donors to approximately 200 nmol/g in donors over 70.

PARP activity (estimated by poly-ADP-ribose immunohistochemistry) showed a significant positive correlation with age, suggesting that progressive oxidative DNA damage drives PARP-mediated NAD+ consumption as a contributor to the age-associated decline. This is distinct from the NAMPT-decline mechanism described by Yoshino et al. and may represent a parallel, tissue-specific driver. The oxidative stress markers 8-OHdG and 4-HNE also correlated positively with age and negatively with NAD+ in this dataset.

A study limitation acknowledged by the authors is that post-mortem tissue NAD+ is subject to post-sampling degradation that can produce systematic underestimates, particularly in samples with longer post-mortem intervals. Nonetheless, the magnitude and consistency of the age-gradient across three tissue types make the main finding robust. For laboratory researchers, this data provides a strong biological rationale for using aged-animal models (18-24-month-old rodents) rather than young animals when designing NAD+ replenishment studies intended to inform aging biology. ^[3]

Study 3, Camacho-Pereira et al., 2016: CD38 as NAD+-ase in Aging

Camacho-Pereira and colleagues used CD38 knockout mice and pharmacological CD38 inhibition to demonstrate that CD38 is the dominant NAD+-consuming enzyme responsible for the tissue NAD+ decline observed during aging. ^[13] Comparing 3-month-old versus 20-month-old wild-type C57BL/6 mice, liver NAD+ fell approximately 60%; in CD38 knockout mice, this age-associated decline was almost completely abolished.

Mechanistically, the authors showed that CD38 expression in liver macrophages (Kupffer cells) increases during aging-associated inflammation, and that this is sufficient to drive whole-tissue NAD+ down. The NAD+ decline preceded measurable changes in NAMPT expression, suggesting that increased CD38 activity is the earlier event. Pharmacological inhibition of CD38 with 78c restored NAD+ levels comparably to CD38 genetic knockout, validating the enzyme as a druggable target.

For experimental design, the study establishes that any in vivo NAD+ replenishment experiment in aged animals will be fighting an active NAD+-ase backdrop. Researchers directly administering NAD+ rather than precursors face the additional complication that extracellular NAD+ is itself a substrate for surface-expressed CD38. Experiments using CD38 inhibition as a combinatorial treatment arm are therefore more interpretable mechanistically than NAD+ alone in aged animal models. ^[13]

Study 4, Gariani et al., 2016: NAD+ and Mitochondrial Biogenesis in Liver Disease

Gariani and colleagues used a mouse model of nonalcoholic steatohepatitis (NASH) to test whether NAD+ precursor supplementation could reverse established metabolic liver disease. ^[15] C57BL/6 mice were fed a high-fat, high-sucrose diet for 16 weeks to induce NASH; the intervention used NR (400 mg/kg/day, oral) for 12 weeks in the established-disease group.

The study documented a marked reduction in hepatic NAD+ (by approximately 55% vs. chow-fed controls) in NASH animals and showed that NR normalized NAD+ levels, which was associated with a 40% increase in hepatic mitochondrial mass (by citrate synthase activity), reduced liver triglycerides, and improvement in histological NASH scores. SIRT1 and SIRT3 activity (as substrate deacetylation status) were both restored by NAD+ normalization.

For researchers using direct NAD+ in cell-culture models of hepatic lipid accumulation, this study provides both a dose-response anchor (restoring NAD+ to approximately 70% of baseline was sufficient for most functional endpoints) and a set of validated endpoints (citrate synthase, SIRT3-AC-SOD2, lipid staining) for use as outcome measures. A limitation is that NR-mediated NAD+ restoration may produce different intracellular distribution of NAD+ than direct extracellular NAD+ delivery. ^[15]

Study 5, Verdin, 2015: NAD+ in the Nervous System and Neurodegeneration

Verdin's comprehensive review in Science synthesized evidence that NAD+ depletion is a conserved feature of neurodegenerative disease models including those of Alzheimer's disease, Parkinson's disease, axonal degeneration, and amyotrophic lateral sclerosis. ^[18] In the context of Wallerian axonal degeneration, the Wld(s) (Wallerian degeneration slow) mutant mouse overexpresses NMNAT, the final enzyme in the NAD+ biosynthesis pathway, and this single enzyme upregulation delays axonal degeneration for 10-fold longer than wild-type animals under nerve crush conditions.

The downstream mechanism involves both energy failure (axons require NAD+/NADH-coupled glycolysis for ATP maintenance) and sirtuin-independent SARM1 activation: SARM1 is an NAD+-glycohydrolase that, when activated by axonal injury, destroys local NAD+ rapidly. The Wld(s) protection appears to operate partly by maintaining local NMNAT activity that outcompetes SARM1-driven NAD+ depletion.

For in vitro neuronal culture applications, Verdin's review highlights that compartmentalized microfluidic chambers can be used to study local NAD+ depletion and supplementation at specific axonal segments, a technically specialized but increasingly accessible approach. Researchers using dissociated cortical or dorsal root ganglion neurons should note that endogenous SARM1 expression in these preparations creates a background NAD+-consuming activity that must be accounted for in dose calibration. ^[18]

Study 6, Elhassan et al., 2019: Skeletal Muscle NAD+ Metabolism in Elderly Humans

Elhassan and colleagues conducted a randomized, placebo-controlled crossover trial in 12 healthy elderly men (mean age 75 years) using NR supplementation at 1,000 mg/day for 21 days. ^[6] Skeletal muscle NAD+ metabolomics revealed that NR increased muscle NAD+ intermediates (NR, NMN, NAD+) measured by LC-MS, with a significant 2-fold elevation in NAAD (nicotinic acid adenine dinucleotide), a marker of NR-specific NAD+ flux.

Although this is a precursor study rather than direct NAD+ administration, it establishes the first human skeletal muscle NAD+ pharmacokinetics data using a validated mass-spectrometry method. The NMN adenylyltransferase-dependent step appeared rate-limiting, as NMN accumulated relative to NAD+ in some subjects. The study enrolled a small n = 12 and was not powered for functional endpoints such as muscle strength or gait speed, which remains a limitation for translation.

For researchers, this study validates the LC-MS skeletal muscle biopsy NAD+ metabolomics method as a suitable outcome measure in translational in vivo work, and the NAD+/NAAD ratio it characterizes provides a reference range for comparing experimental vs. control animals in rodent studies using the same analytical method. ^[6]

Additional Pharmacological Evidence

Multiple rodent studies from Imai and colleagues at Washington University have used genetic NAMPT overexpression (establishing elevated baseline NAD+) and NAMPT knockout (establishing NAD+ deficiency) to build a comprehensive gene-function map. Muscle-specific NAMPT knockout mice develop a mitochondrial myopathy with progressive reduction in Type I and IIa fiber content, consistent with a model in which sustained NAD+ deficiency is sufficient to produce fiber-type switching toward fast-glycolytic, less mitochondria-rich muscle. ^[7] Conversely, muscle-specific NAMPT overexpression produces increased exercise capacity, improved insulin sensitivity, and partial protection from high-fat-diet-induced muscle loss. These genetic models provide clean mechanistic support for the role of NAD+ in muscle biology independent of pharmacokinetic confounds.

Pharmacokinetics

Membrane Permeability and Cellular Uptake

The membrane impermeability of intact NAD+ is a critical pharmacokinetic reality that distinguishes it from many research peptides. The molecule carries a net negative charge at physiological pH due to its pyrophosphate backbone and is too large (MW 663 g/mol) and too polar to cross lipid bilayers by passive diffusion. ^[2]

Cellular uptake studies using isotope-labeled NAD+ have consistently shown that extracellular NAD+ must first be hydrolyzed to NMN plus AMP (by surface-expressed CD73, ENPP1, or ENPP3) or further to NR (by CD73 from NMN), and the smaller fragments enter cells through equilibrative nucleoside transporters (ENTs) or the Slc12a8 NMN transporter. ^[7] Intracellular NAD+ is then resynthesized from these fragments by NMNAT isoforms.

The practical implication for in vitro work is that extracellular NAD+ added to culture medium acts primarily as a precursor pool. Researchers aiming for a specific intracellular NAD+ target concentration need to titrate empirically and confirm intracellular levels by extraction and LC-MS or fluorometric cycling assay, rather than assuming a fixed extracellular-to-intracellular ratio.

Stability Considerations for Stock Preparation

Reconstituted NAD+ in aqueous solution degrades measurably within hours at 37°C. The primary degradation pathway is base-catalyzed hydrolysis of the N-glycosidic bond under alkaline conditions (pH > 7.5), releasing nicotinamide and adenosine-diphosphoribose (ADPR). Acid-catalyzed hydrolysis also occurs below pH 4, releasing nicotinamide from the N-glycosidic bond. ^[1]

For researchers preparing stock solutions, the optimal strategy is to dissolve NAD+ in sterile water or PBS adjusted to pH 6.0-6.5, prepare at a high concentration (50-100 mM) to minimize the volume added to experiments, aliquot immediately into single-use volumes, snap-freeze in liquid nitrogen, and store at -80°C. Freeze-thaw cycling produces incremental degradation with each cycle; for high-precision kinetic studies, working from freshly prepared solutions is preferable even at the cost of increased material consumption.

Guidance on detailed reconstitution protocol steps, including sterile technique and equipment selection, is available in our reconstitution guide.

Purity and Verification

What a Valid CoA Contains

A certificate of analysis from a credible supplier for NAD+ research grade should include at minimum: lot number, manufacture date, expiration date, HPLC chromatogram with peak integration showing NAD+ purity 95% or greater, mass spectrometry confirmation of the correct molecular ion (m/z 664 for [M+H]+, or the sodium adduct at m/z 686), residual solvent analysis (particularly relevant for material that passed through synthesis or purification steps using organic solvents), and water content by Karl Fischer titration (lyophilized NAD+ typically retains 2-8% residual water, which affects the true mass of compound delivered per vial if not accounted for).

HPLC method specifications should state the column type (C18 reverse-phase is standard), mobile phase (aqueous ammonium acetate/methanol gradient is commonly reported), detection wavelength (260 nm), and injection volume. A single-peak chromatogram with no visible shoulder or satellite peak at the NAD+ retention time is the minimum acceptable output. A co-eluting NADH peak at longer retention time is an indicator of partial reduction during storage or synthesis.

Independent Verification Approaches

Researchers purchasing bulk NAD+ for repeated use are advised to implement at minimum one independent verification step per lot before committing the material to long-duration experiments. The most accessible approach is the enzymatic cycling assay: NAD+ is converted to NADH by alcohol dehydrogenase, and NADH is recycled by a diaphorase-coupled reduction of a tetrazolium salt to a colored formazan. The absorbance at 450-570 nm is linear from approximately 50 nM to 10 µM, providing quantitative concentration verification. Commercial kits (Sigma-Aldrich MAK037, Abcam ab65348) include all reagents and reference standards for less than $300 per 100 assays.

For higher confidence, LC-MS identity confirmation using a short C18 column with an aqueous/acetonitrile gradient and a single quadrupole or triple-quadrupole mass detector provides definitive identity alongside retention-time comparison to a certified reference standard (CRS) purchased from Sigma-Aldrich or Cayman Chemical. This approach costs approximately $50-80 of analytical time per sample and should be considered mandatory for GLP-adjacent work or any experiment where the NAD+ biology result will anchor a downstream publication. A detailed guide to interpreting supplier CoA documents is available at /guides/how-to-read-a-coa.

Dosage and Reconstitution

Literature-Reported Research Concentrations

In vitro (cell culture): The most commonly cited range for NAD+ supplementation in mammalian cell-culture experiments is 0.5-5 mM in the culture medium. At 0.5 mM, studies in senescent human dermal fibroblasts and IMR-90 lung fibroblasts have reported partial rescue of senescence-associated secretory phenotype (SASP) markers. ^[3] At 2-5 mM, studies in HEK293T and liver-derived cell lines (HepG2) have measured statistically significant increases in SIRT1 and SIRT3 deacetylase activity. ^[8] Concentrations above 10 mM are rarely used and have been associated with cytotoxicity in high-passage human cell lines, likely related to osmotic stress rather than direct NAD+ toxicity.

Ex vivo (tissue preparations): Isolated mitochondria experiments typically use 0.5-1 mM NAD+ in the assay buffer to saturate Complex I and maintain NADH cycling capacity. Permeabilized fiber bundles from skeletal muscle biopsy preparations use 2 mM NAD+ in the respiration buffer to approximate physiological matrix concentrations.

In vivo (rodent models, literature-reported): Intraperitoneal administration studies in C57BL/6 mice have used single doses of 100-500 mg/kg in normal saline, or chronic daily dosing at 300 mg/kg for up to 12 weeks. ^[6] These are not human doses; they reflect rodent-specific experimental designs aimed at rapidly raising tissue NAD+ above baseline to test biological hypotheses. Oral gavage studies have generally used higher doses (500-1,000 mg/kg) due to expected gastrointestinal hydrolysis and low bioavailability of intact NAD+ by the oral route.

Reconstitution Worked Examples

Full reconstitution technique, sterile filtration steps, and storage recommendations are covered in detail at /guides/how-to-reconstitute-peptides. Dosage calculation math is at /guides/how-to-calculate-dosage. Three worked numerical examples relevant to NAD+ are provided below.

Example 1, 10 mM stock solution from 1,000 mg vial

NAD+ MW (free acid) = 663.43 g/mol. Target: 10 mM stock in sterile water for cell-culture use. Required volume = (mass in mg) / (MW in g/mol × target molarity × 10-3) = 1,000 mg / (663.43 g/mol × 10 mmol/L × 10-3 L/mL) = 1,000 / 6.6343 = 150.7 mL of sterile water. Result: Adding 150.7 mL of sterile water to the 1,000 mg vial yields a 10 mM stock (pH-adjusted to 6.0-6.5 before use). Aliquot into 1 mL single-use tubes, snap-freeze, and store at -80°C.

Example 2, 1 mM working concentration in 10 mL of culture medium

Using the 10 mM stock above, prepare a 1:10 dilution: add 1.0 mL of 10 mM stock to 9.0 mL of complete culture medium (warmed to 37°C, pH pre-equilibrated). Final NAD+ concentration = 1 mM in 10 mL. This volume treats approximately 20 standard 96-well plates at 500 µL per well (50 wells per mL), or three 6-well plates at 2 mL per well. Check medium pH after addition; NAD+ at 1 mM does not measurably shift pH of well-buffered DMEM but may affect minimally buffered phenol-red-free formulations.

Example 3, Dose calculation for a 25g mouse (300 mg/kg IP)

Target dose: 300 mg/kg intraperitoneal in a 25 g C57BL/6 mouse. Dose per mouse = 300 mg/kg × 0.025 kg = 7.5 mg per mouse. Using a 50 mg/mL solution in sterile saline: volume = 7.5 mg / 50 mg/mL = 0.15 mL (150 µL). 150 µL IP is within accepted rodent IP volume limits (up to 10 mL/kg = 250 µL for a 25 g mouse). A 1,000 mg vial at this dose yields approximately 133 injections, sufficient for approximately 3-4 animals per day over a 4-week study at daily dosing.

Storage After Reconstitution

Reconstituted aqueous NAD+ stocks stored at -80°C retain greater than 90% purity for approximately 12 weeks when freeze-thawed no more than three times, based on HPLC stability-testing data from published method-development papers. Working solutions prepared daily at 37°C should be freshly made and any remainder discarded at end of the experiment day.

Side Effects and Safety

Safety Profile in Preclinical Models

In rodent acute toxicity studies, intraperitoneal NAD+ at doses up to 2,000 mg/kg has not been associated with observable mortality in C57BL/6 mice across short observation windows (24-48 hours), consistent with the expected tolerability of an endogenous metabolite at supraphysiological but not pharmacologically extreme doses. ^[6] Subchronic daily IP dosing at 300 mg/kg for 12 weeks in the Gariani et al. NR protocol (which produces tissue NAD+ levels broadly comparable to direct NAD+ dosing at similar concentrations) showed no histological abnormalities in liver, kidney, or heart in NR-treated animals.

Chronic elevations in NAD+ above physiological range have theoretical risks related to excessive PARP activation (which at very high NAD+ concentrations could theoretically sustain PAR chain elongation in the absence of DNA damage) and to over-activation of CD38 (which could dysregulate calcium homeostasis in cardiac tissue). These risks have not been demonstrated at research doses in published rodent literature but remain mechanistically plausible considerations for study design.

Handling Precautions

NAD+ powder is not classified as a hazardous substance under GHS criteria. Standard laboratory PPE (gloves, lab coat, eye protection) is adequate for handling. The powder is hygroscopic and should be weighed and reconstituted in a low-humidity environment where possible. There are no known sensitization or irritation risks at research concentrations, but researchers with known hypersensitivity to nicotinamide or adenine should exercise caution given the structural components.

Aqueous solutions above 50 mM may cause localized irritation to mucous membranes; standard laboratory handling practice of avoiding pipetting with bare hands and working in a biosafety cabinet when preparing solutions for animal studies applies. Disposal should follow institutional waste management protocols for biological reagents, as NAD+ is readily biodegradable.

Contamination Risk

The primary safety concern specific to research-grade NAD+ is lot-to-lot contamination with related metabolites (NADH, AMP, nicotinamide) or residual solvents from synthesis. These contaminants do not pose acute hazard at research concentrations but can invalidate experimental results. Verification of purity before use (as described in the Purity and Verification section above) is the primary mitigation.

How It Compares

Choosing Between NAD+ and Its Precursors

The choice between direct NAD+ and biosynthetic precursors (NMN, NR) is a common decision point for researchers new to NAD+ biology. The answer depends on the experimental question.

Direct NAD+ is the appropriate choice when the experimental design requires a precisely defined exogenous substrate load, when the study is testing PARP or sirtuin kinetics at known substrate concentrations, or when the cell line of interest has been shown to have limited NMN or NR uptake (common in post-mitotic neurons and some primary cell preparations). The drawback is low intrinsic cell permeability, requiring higher medium concentrations to achieve target intracellular levels.

NMN is the appropriate choice when the experiment aims to model the endogenous biosynthetic pathway or when intracellular NAD+ elevation must be sustained over days rather than hours. The Slc12a8 transporter provides efficient NMN uptake in most cell types, and the single NMNAT-catalyzed step to NAD+ is rapid. However, NMN is more expensive per mole than NAD+ and requires its own purity verification given its structural similarity to AMP.

NR offers the best bioavailability profile for in vivo oral supplementation studies due to efficient intestinal nucleoside transporter uptake and first-pass hepatic conversion to NMN and NAD+. For in vitro use, the two-step conversion (NR to NMN via NRK, then NMN to NAD+ via NMNAT) is slower than NMN but still achieves sustained intracellular NAD+ elevation within 6-12 hours. ^[7]

The bulk 1,000 mg NAD+ format reviewed here is most cost-effective when direct substrate is needed for repeat experiments at the scale where 10-50 mg per experiment is consumed. For pilot experiments or work requiring only microgram quantities, smaller format vials reduce waste and stability risk.

Comparison to Sirtuin-Activating Compounds (STACs)

Resveratrol and the more potent synthetic STACs (SRT1720, SRT2104) activate SIRT1 allosterically rather than by raising substrate NAD+ levels. They do not compete with NAD+ as a substrate and can theoretically activate SIRT1 even at low NAD+ concentrations, though this claim has been contested. The experimental utility of STACs vs. NAD+ supplementation is an active area; mechanistically, NAD+ supplementation addresses the cosubstrate availability arm of sirtuin regulation while STACs address the allosteric activation arm. Using both in factorial experiments can help dissect how these two regulatory inputs interact, an approach used by Auwerx and colleagues in multiple aging-biology studies. ^[9]

Where to Buy

Apollo Peptide Sciences supplies this compound as a 1,000 mg lyophilized vial at $100.00. You can view the full product details, current lot CoA, and the affiliate-linked purchase option on our NAD+ 1000mg product page.

When evaluating any supplier for bulk NAD+ research material, the following selection criteria should be applied systematically. First, confirm that the supplier publishes a lot-specific CoA (not a generic document) and that the HPLC purity specification is 95% or higher with a visible chromatogram. Second, confirm that mass spectrometry identity data is included. Third, check that the supplier can describe their cold-chain shipping method; NAD+ shipped at ambient temperature for multiple days is likely to show measurable degradation. Fourth, review independent third-party testing or accreditation where available.

Our general supplier evaluation framework, including how to cross-check CoA claims with independent analytical methods, is at /suppliers.

For researchers who want a broader overview of where NAD+ biology compounds fit within our full longevity research category, the /best-for/longevity roundup provides comparative context alongside related products in this category.

Open Research Questions

The NAD+ biology field has produced a large and internally consistent body of work on the relationship between declining NAD+ and aging phenotypes. However, several questions remain unresolved and should inform how researchers interpret their data and design their next experiments.

Is Intracellular NAD+ Actually Rate-Limiting for Sirtuin Activity In Vivo?

The kinetic argument for NAD+ supplementation activating sirtuins is based on in vitro Km measurements showing that SIRT1 is not saturated at normal cellular NAD+ concentrations. However, some groups have argued that substrate channeling within protein complexes (where NAMPT, NMNAT, and SIRT1 may form a metabolon) effectively provides a locally high NAD+ concentration to sirtuins regardless of bulk cytoplasmic NAD+. If this is correct, raising bulk NAD+ may not proportionally increase sirtuin activity. Evidence on both sides exists; the Guarente lab supports the substrate-limitation model while other groups have produced data suggesting that SIRT1 activity is primarily regulated by allosteric mechanisms and post-translational modifications rather than substrate availability. Resolution of this question will likely require single-cell NAD+ imaging combined with real-time SIRT1 activity reporters.

What Is the Relative Contribution of Mitochondrial vs. Cytoplasmic NAD+ to Aging Phenotypes?

Mitochondrial and cytoplasmic NAD+ pools appear to be regulated semi-independently. NMNAT3 in mitochondria may be limiting for mitochondrial NAD+ synthesis from NMN, while cytoplasmic SIRT1 and nuclear SIRT6 draw from the nuclear/cytoplasmic pool. ^[16] Current supplementation approaches with exogenous NAD+ or its precursors likely preferentially affect cytoplasmic pools; whether mitochondrial NAD+ is co-elevated is uncertain and probably cell-type dependent. This matters because the strongest aging phenotypes in muscle and liver may be driven specifically by mitochondrial NAD+ decline.

Does CD38 Inhibition Synergize with NAD+ Supplementation?

Camacho-Pereira et al. established CD38 as a major NAD+-consuming enzyme in aged tissue. ^[13] The logical extension is that combining CD38 inhibition with direct NAD+ supplementation should produce synergistic NAD+ elevation. While this has been demonstrated in isolated cell preparations, the systemic consequence of sustained CD38 inhibition in vivo (given CD38's role in calcium signaling in cardiomyocytes and immune-cell activation) has not been fully characterized. Researchers designing combination experiments should monitor cardiac function markers and immune cell phenotyping as safety endpoints.

Human Translational Evidence Remains Sparse

The vast majority of NAD+ mechanism data derives from rodent models or cell-culture work. Human studies using NR or NMN supplementation confirm that these precursors raise blood and tissue NAD+ measurably, ^[6] but controlled evidence linking NAD+ elevation to functional endpoints in humans (cognitive performance, muscle strength, cardiovascular function) is inconsistent and largely from underpowered trials. This is not an argument against the mechanistic biology but is a legitimate scientific limitation that should be reflected in how researchers communicate their findings.

FAQ